Trial Profile
Effects of an everolimus-eluting bioresorbable vascular scaffold in patients with lesions involving side branches
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Jan 2014
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- 03 Jan 2014 New trial record